ZEISS Presents Diagnostic and Surgical Advancements at ASCRS
The latest technologies from ZEISS help doctors advance ophthalmic care with new ways to see pathology and maximize clinical efficiency and performance
16 Apr 2018The Medical Technology business group of ZEISS presented its latest ophthalmic diagnostic and surgical advancements at the 2018 American Society of Cataract and Refractive Surgery’s Annual Meeting, April 13-17, Washington, D.C. ZEISS is also hosting three symposia and informative sessions with renowned experts throughout the event.
ZEISS presented its complete portfolio of integrated diagnostic and surgical solutions that help cataract surgeons work more efficiently and deliver excellent outcomes for their patients. Using ZEISS Cataract Suite Markerless, with the OPMI LUMERA® surgical microscope and CALLISTO® eye, the computer-assisted surgery system that enables the exchange of data between diagnostics and the OR, surgeons can more easily and precisely align toric IOLs, skipping the manual pre- and intra-operative marking steps and manual data transfer. IOLMaster® 700 Swept Source Biometry, when integrated into the toric IOL workflow of ZEISS Cataract Suite Markerless, helps surgeons achieve target refraction and reduce the risk of refractive surprises for improved refractive outcomes for their patients.
Click here to find out more about the latest products from ZEISS >>
Also on display during ASCRS will be VERACITY™ Surgical from ZEISS an intuitive cloud-based platform for cataract surgery planning, logistics, treatment, risk management, and analysis. This latest digital connected eye care technology from ZEISS provides personalized technology-enabled patient care, synthesizing critical data at each step of the procedure to help cataract surgeons work more efficiently and reduce risks.
“We are continuing to expand our portfolio of integrated digital solutions that span from the office to the OR,” says Jim Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec. “Digitalization presents many opportunities to improve treatment outcomes and increase the efficiency of clinical workflows. Our goal is to continue to provide doctors and surgeons advanced technologies to help them care for their patients in the best way possible.”
Surpassing milestone of 1M procedures worldwide, ZEISS celebrates one year of SMILE laser vision correction in the USA
ReLEx® SMILE (Small Incision Lenticule Extraction) laser eye surgery is now being performed regularly around the world having been adopted by over 1300 surgeons in 69 countries, surpassing one million procedures worldwide. Using the VisuMax® femtosecond laser from ZEISS, SMILE provides refractive surgeons an additional proven laser vision correction option to offer their patients. A new clinical trial has begun outside the USA for SMILE in hyperopic patients. VisuMax Intracorneal Tunnel Cutting Option Page 2 (ICR), which allows versatile incisions for the implantation of intracorneal rings, is now 510(k) cleared.
Professor Dan Z. Reinstein will be moderating a panel of experts to look back at the last year of SMILE at the ZEISS Meet the Experts session, “SMILE Adoption: Critical First Steps.” He will also be available during the ASCRS to sign copies of his newly released book, “The Surgeon's Guide to SMILE: Small Incision Lenticule Extraction.”
Don’t miss out on the latest clinical diagnostic news, visit the Clinical Diagnostic Community >>
ZEISS Swept-Source OCT advancements pushing forward discovery in retinal research
Since its inauguration in 2016, the A R I Network, a global consortium of renowned doctors, clinicians, and scientists, has collaborated with ZEISS to advance the field of retinal imaging to drive further discovery and breakthroughs of new clinical applications for diseases affecting the retina. Having access to the latest Swept-Source OCT technology from ZEISS and with its Open Innovation approach, the A R I Network enables the exchange of ideas between members from around the world, facilitating collaboration to accelerate OCT development with ZEISS scientists. To date, the A R I Network has over 90 ongoing collaborative efforts to advance clinical practice and patient care, with over 45 publications and 60 posters.
“The A R I Network is a perfect example of how ZEISS collaborates with experts in their fields to develop new innovative solutions to advance patient care and to bring these technologies to everyday clinical use,” says Dr. Ludwin Monz, President, and CEO of Carl Zeiss Meditec.
As a result of the A R I Network collaboration, new advanced technologies are being integrated into the PLEX® Elite 9000 Swept-Source OCT / OCTA platform from ZEISS to further doctors’ understanding and analysis of the critical vasculature of the eye. Among these advancements include visualization tools enabling wider and deeper imaging of the eye, for improved visualization of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy. These new visualization technologies developed for PLEX Elite have been integrated into the CIRRUS® OCT and OCT Angiography platforms for use in daily clinical practice. Both instruments along with the recently launched ultra-widefield fundus imaging system, CLARUS™ 500, are part of ZEISS’ comprehensive diagnostic portfolio.
Do you use products from ZEISS in your laboratory? Write a review today for your chance to win a $400 Amazon voucher.